Morning Briefing
Summaries of health policy coverage from major news organizations
Pfizer Shot Shown To Be Extremely Effective Against Asymptomatic Covid
CBS News: Pfizer Vaccine 97% Effective Against Symptomatic COVID-19, Study Shows
Pfizer-BioNtech's coronavirus vaccine offers more protection than earlier thought, with effectiveness in preventing symptomatic disease reaching 97%, according to real-world evidence published Thursday by the pharma companies. Using data from January 17 to March 6 from Israel's national vaccination campaign, Pfizer-BioNtech found that prevention against asymptomatic disease also reached 94 percent. (3/11)
Axios: Pfizer Data From Israel Finds Vaccine Prevents 94% Of Asymptomatic Infections
The latest analysis from Israel, where a world-leading 44% of the population has received two vaccine doses, suggests that the Pfizer vaccine could significantly reduce asymptomatic transmission — a key driver of infections — in addition to preventing severe illness and death. (Gonzalez, 3/11)
ABC News: Pfizer Vaccine Shows 94% Effectiveness Against Asymptomatic Transmission Of COVID
As concerning COVID variants spread and the companies behind the three authorized vaccines hurry to test their shots against them, there's other promising news from Thursday's announcement: this latest analysis was performed when more than 80% of Israel's COVID-19 cases were from the UK variant B.1.1.7 -- demonstrating that the Pfizer vaccine is equally effective against this variant, which is known to be more contagious, and possibly even more deadly, Israel's Ministry of Health reported. (Silberman, 3/11)
In other news about Pfizer and Moderna —
NPR: Pfizer And Moderna Make Progress On COVID-19 Vaccine Goals
Distributions skyrocketed the last two weeks, according to an NPR analysis of archived data from the CDC's vaccination tracker. Since early January, they wobbled between 8 million and 10 million total doses a week. But in both the last week of February and again the first week of March, the companies delivered around 20 million doses. If Pfizer and Moderna can keep it up, they'll both hit 100 million. Both companies have expressed confidence. In a statement to NPR, Pfizer spokesman Steven Danehy also reiterated a promise CEO Albert Bourla made in late January to deliver even more doses by the end of the month. (Lupkin, 3/11)
KHN: To Extract More Doses Per Vial, Vaccinators Put Squeeze On FDA To Relax Vaccine Handling Advice
President Joe Biden has promised enough covid vaccine to immunize every willing adult by June 1. But right now, the gap between supply and demand is so dramatic that vaccinators are discovering ways to suck the final drops out of each vaccine vial — if federal regulators will let them. Pharmacists involved in the covid vaccination drive say it’s common to have half a dose left in a Pfizer vial after five or even six doses have been administered — and to have half a dose left after 10 doses have been drawn out of a Moderna vial. Combining two half-doses could increase vaccinations by thousands at a time when 2 million or so doses are being administered every day in the country. (Allen, 3/12)
KHN: ‘Explained By KHN’: Consumer Concerns About The Covid Vaccines
The twists and turns of the American health system can sometimes leave people lost, confused and looking for answers. We’ve created a new video series — “Explained by KHN” — in which our correspondents and editors answer common health care and health policy questions. As promising news about the development, efficacy and distribution of covid-19 vaccines spread across the United States, questions about the shots were even more viral. In this edition of “Explained by KHN” we will answer common consumer questions about the covid vaccines. (Allen, Appleby and Lofton, 3/12)
